Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide

European Journal of Endocrinology

Volumn 158, Issue 3, 2008, Pages 411-415

  Anastasilakis, Athanasios D ^a,e   Goulis, Dimirtios G ^b   Polyzos, Stergios A ^a   Gerou, Spiridon ^c   Pavlidou, Vasiliki ^c   Koukoulis, George ^d   Avramidis, Avraam ^a  

^a Aristotle University of Thessaloniki   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c Laboratories Analysis   (Greece)

^d UNIVERSITY OF THESSALY   (Greece)

^e NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; COLLAGEN TYPE 1; COLLAGEN TYPE 1 AMINOTERMINAL PROPEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE[1-34]; PHOSPHATE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUMBAR SPINE; OSTEOBLAST; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ALKALINE PHOSPHATASE; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; PHOSPHORUS; PROSPECTIVE STUDIES; RANK LIGAND; TERIPARATIDE;

EID: 40949139638     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0528     Document Type: Article

References (28)

1. Hodsman A, Bauer D, Dempster D, Dian L, Hanley D, Harris S, Kendler D, McClung M, Miller P, Olszynski W, Orwoll E & Yuen C. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocrine Reviews 2005 26 688-703.
2. Gori F, Hofbauer L, Dunstan C, Spelsberg T, Khosla S & Riggs B. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000 141 4768-4776.
3. Hofbauer L & Heufelder A. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. Journal of Clinical Endocrinology and Metabolism 2000 85 2355-2363.
4. Huang J, Sakata T, Pfleger L, Bencsik M, Halloran B, Bikle D & Nissenson R. PTH differentially regulates expression of RANKL and OPG. Journal of Bone and Mineral Research 2004 19 235-244.
5. Lee S & Lorenzo J. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999 140 3552-3561.
6. Kondo H, Guo J & Bringhurst F. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. Journal of Bone and Mineral Research 2002 17 1667-1679.
7. Coetzee M, Haag M & Kruger M. Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. Journal of Nutritional Biochemistry 2007 18 54-63.
8. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo J, Martin T, Nagai K & Suda T. Intraceliular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000 141 4711-4719.
9. Wang L, Quarles L & Spurney R. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH (1-34). Journal of Bone and Mineral Research 2004 19 1661-1670.
10. Iida-Klein A, Zhou H, Lu S, Levine L, Ducayen-Knowles M, Dempster D, Nieves J & Lindsay R. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. Journal of Bone and Mineral Research 2002 17 808-816.
11. Ma Y, Cain R, Halladay D, Yang X, Zeng Q, Miles R, Chandrasekhar S, Martin T & Onyia J. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 2001 142 4047-4054.
12. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K & Suda T. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. Journal of Cellular Biochemistry 2003 90 267-277.
13. Stilgren L, Rettmer E, Eriksen E, Hegedus L, Beck-Nielsen H & Abrahamsen B. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-κb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Bone 2004 35 256-265.
14. Stilgren L, Hegedus L, Beck-Nielsen H & Abrahamsen B. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Calcified Tissue International 2003 73 210-216.
15. Seck T, Diel I, Bismar H, Ziegler R & Pfeilschifter J. Serum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samples. European Journal of Endocrinology 2001 145 199-205.
16. Buxton E, Yao W & Lane N. Changes in serum receptor activator of nuclear factor-κB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). Journal of Clinical Endocrinology and Metabolism 2004 89 3332-3336.
17. Hofbauer L & Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. Journal of the American Medical Association 2004 292 490-495.
18. Rogers A & Richard E. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. Journal of Clinical Endocrinology and Metabolism 2005 90 6323-6331.
19. Khosla S, Atkinson E, Dunstan C & O'Fallon W. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. Journal of Clinical Endocrinology and Metabolism 2002 87 1550-1554.
20. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L, Gallagher J, Pavo I, Wang J & Eriksen E. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. Journal of Clinical Endocrinology and Metabolism 2005 90 3970-3977.
21. Neer R, Arnaud C, Zanchetta J, Prince R, Gaich G, Reginster J, Hodsman A, Eriksen E, Ish-Shalom S, Genant H, Wang O & Mitlak B. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine 2001 344 1434-1441.
22. Kinyamu H, Gallagher J, Petranick K & Ryschon K. Effect of parathyroid hormone (hPTH(1-34)) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women. Journal of Bone and Mineral Research 1996 11 1400-1405.
23. Cosman F, Shen V, Herrington B & Lindsay R. Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) (PTH-(1-34)): demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay. Journal of Clinical Endocrinology and Metabolism 1991 73 1345-1351.
24. Chen D, Sarikaya N, Gunn H, Martin S & Young J. ELISA methodology for detection of modified osteoprotegerin in clinical studies. Clinical Chemistry 2001 47 747-749.
25. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle W, Lacey D & Riggs B. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. Journal of Clinical Investigations 2003 111 1221-1230.
26. Rubin J, Ackert-Bicknell C, Zhu L, Fan X, Murphy T, Nanes M, Marcus R, Holloway L, Beamer W & Rosen C. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-κB Ligand in vitro and OPG in vivo. Journal of Clinical Endocrinology and Metabolism 2002 87 4273-4279.
27. Ma Y, Zeng Q, Donley D, Ste-Marie L, Gallagher J, Dalsky G, Marcus R & Eriksen E. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 2006 21 855-864.
28. Canalis E, Giustina A & Bilezikian J. Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine 2007 357 905-916.